Biomarkers of Response to Immune Checkpoint Inhibitor Therapy in Colorectal Cancer: Practical Guidance for Oncologists and Pathologists

Explore key issues in leveraging response biomarkers for immune checkpoint therapy in colorectal cancer! Gain expert insights with CME-certified text modules, CME-certified video, ClinicalThought commentaries, and a summary resource guide on how to optimize therapy selection with immune response markers.
Robert A. Anders, MD, PhD
Tanios Bekaii-Saab
Tanios Bekaii-Saab, MD, FACP
Feriyl Bhaijee, MD
Scott Kopetz, MD, PhD, FACP
John L. Marshall, MD
Dipen Maru, MD

Modules

In this module, John L. Marshall, MD, reviews practice-changing immunotherapy options for patients with metastatic colorectal cancer, as well as biomarkers that predict response to immune checkpoint inhibitors and the latest data supporting their use in GI malignancies.

John L. Marshall, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: June 21, 2017 Expiration: June 20, 2018

In this downloadable slideset, John L. Marshall, MD, reviews the latest clinical data on biomarkers of response to immune checkpoint inhibitors in CRC. These slides accompany the CME-certified Clinical Focus module comprising Dr. Marshall’s expert in-depth discussion.

Released: June 21, 2017

In this interactive, CME-certified module, Dipen Maru, MD, provides his perspective on how to leverage biomarkers of response to immune checkpoint inhibitors to optimize the care of patients with colorectal cancer.

Dipen Maru, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: April 19, 2017 Expiration: April 18, 2018

In this downloadable slideset, Dipen Maru, MD, reviews the latest pathology data on biomarkers of response to immune checkpoint inhibitors in CRC. These slides accompany the CME-certified Clinical Focus module comprising Dr. Maru’s expert in-depth discussion.

Released: April 19, 2017

Clinician Resource PDF

In this downloadable resource, expert faculty John L. Marshall, MD, reviews key testing methods for microsatellite instability, PD-L1, and other biomarkers of response to immune checkpoint inhibitors in patients with colorectal cancer. For additional in-depth analysis, please review the accompanying CME-certified text modules, downloadable slides, and ClinicalThought commentaries for expert guidance on the optimal use of immunotherapy in colorectal cancer.

Released: June 26, 2017

Video Module

In this video module, watch our distinguished faculty discuss how oncologists and pathologists can leverage established and emerging biomarkers to guide immunotherapy selection in advanced colorectal cancer.

Feriyl Bhaijee, MD Scott Kopetz, MD, PhD, FACP John L. Marshall, MD Dipen Maru, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: August 18, 2017 Expiration: August 17, 2018

ClinicalThought

Using MSI and MMR testing to inform treatment decisions with immune checkpoint inhibitors is improving outcomes in colorectal cancer, but many questions remain. Read our thoughts on how these tools are improving clinical practice.

Robert A. Anders, MD, PhD Released: April 25, 2017

How can immune checkpoint inhibitors improve outcomes in patients with high-risk, progressive colorectal cancer? Read my thoughts on how I incorporate these agents into my practice.

Scott Kopetz, MD, PhD, FACP Released: May 10, 2017

With the first immunotherapy agent approved for use in colorectal cancer, how is this going to change your practice?

Tanios Bekaii-Saab Tanios Bekaii-Saab, MD, FACP Released: June 21, 2017

Should we evaluate microsatellite status in all patients with colorectal cancer, regardless of stage and treatment experience? Read my thoughts on how I approach testing in my practice.

John L. Marshall, MD Released: July 11, 2017
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

This activity is supported by an educational grant from
Bristol-Myers Squibb

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?